HIGHLIGHTS
- who: Pampina Pilavaki and collaborators from the Duke University, United States have published the paper: Exploring the landscape of immunotherapy approaches in sarcomas, in the Journal: (JOURNAL)
- what: Regarding the antitumour activity, 3 confirmed PRs were reported, 1 unconfirmed PR at week 6, 3 SD, 1 PD, and 2 patients were not evaluated. Anti-tumour activity has been observed in different types of sarcomas with tolerable toxicity and further investigation of therapy with T-VEC and pembrolizumab in certain histological types of sarcomas is being pursued.
- how: Among the 14 participants who were . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.